Last month, the FDA announced that it would be conducting a safety review of Pradaxa. Pradaxa is a blood thinning drug typically used in patients who suffer from non-valvular atrial fibrillation. The drug is intended to thin the blood to prevent blood clots from traveling to the brain and causing stroke.
Currently the FDA is investigating whether dangerous bleeding in Pradaxa patients is occurring more commonly than should be expected.
While the FDA believes that Praxa provides important benefits, it is urging doctors to closely follow the recommendations on the drug warning label. Patients taking Pradaxa should continue to do so as directed by their doctor and review any concerns or potential warning signs of dangerous side effects with their physicians.
